

IGF 1, LC/MS

Z SCORE (FEMALE)

Specimen:			
Requisition:			
Lab Ref #:			
C-111-			
Reported:			
In Range	Out Of Rang	e Reference Range	La
	39 H	22-35 %	
	K	ererence kange	
	>	or = 20 Years 0.40-4.50	
		Pregnancy Ranges	
3 2	Z.Z П		
		Lab Ref #: Collected: Received: Reported: In Range Out Of Rang 39 H 14.1 H 5.5 H <0.01 L R 2.2 H	Lab Ref #: Collected: Received: Reported: In Range Out Of Range Reference Range 39 H

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute San Juan Capistrano. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

274

1.5

```
CORTISOL, TOTAL
                                   12.2
                                                               mcg/dL
     Reference Range: For 8 a.m.(7-9 a.m.) Specimen: 4.0-22.0
     Reference Range: For 4 p.m.(3-5 p.m.) Specimen: 3.0-17.0
       * Please interpret above results accordingly *
```

171 23-266 mcg/dL DHEA SULFATE FSH 125.8 H mIU/mL

Reference Range

Follicular Phase 2.5-10.2 Mid-cycle Peak 3.1 - 17.71.5- 9.1 Luteal Phase Postmenopausal 23.0-116.3

51.9 LH mIU/mL Reference Range Follicular Phase 1.9-12.5 Mid-Cycle Peak 8.7-76.3

Luteal Phase 0.5 - 16.910.0-54.7 Postmenopausal < 0.5 ng/mL PROGESTERONE

Reference Ranges Female

Follicular Phase < 1.0 Luteal Phase 2.6-21.5 Post menopausal < 0.5 Pregnancy

-2.0 - +2.0 SD

53-331 ng/mL

< or = 31



Patient Information	Specimen Information	Client Information
	Specimen:	
	Collected:	
DOB: AGE:	Received:	
Gender:	Reported:	
Patient ID:		

Test Name In Range Out Of Range Reference Range Lab 1st Trimester 4.1 - 34.02nd Trimester 24.0-76.0 52.0-302.0 3rd Trimester pg/mL ESTRADIOL 26 Reference Range 19-144 Follicular Phase: Mid-Cycle: 64-357 Luteal Phase: 56-214

Reference range established on post-pubertal patient population. No pre-pubertal reference range established using this assay. For any patients for whom low Estradiol levels are anticipated (e.g. males, pre-pubertal children and hypogonadal/post-menopausal females), the Quest Diagnostics Nichols Institute Estradiol, Ultrasensitive, LCMSMS assay is recommended (order code 30289).

Please note: patients being treated with the drug fulvestrant (Faslodex(R)) have demonstrated significant interference in immunoassay methods for estradiol measurement. The cross reactivity could lead to falsely elevated estradiol test results leading to an inappropriate clinical assessment of estrogen status. Quest Diagnostics order code 30289-Estradiol, Ultrasensitive LC/MS/MS demonstrates negligible cross reactivity with fulvestrant.

37

TESTOSTERONE, FREE

(DIALYSIS) AND TOTAL, MS
TESTOSTERONE TOTAL MS

TESTOSTERONE, TOTAL, MS

2-45 ng/dL

Postmenopausal:

For additional information, please refer to http://education.questdiagnostics.com/faq/TotalTestosteroneLCMSMSFAQ165 (This link is being provided for informational/educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.

TESTOSTERONE, FREE

2.6

0.1-6.4 pg/mL

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Chantilly, VA. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.



Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Patient ID:	Specimen: Collected: Received: Reported:	

PERFORMING SITE: